Edgewise Therapeutics (EWTX) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 161.4% versus a gain of 11.8%. Edgewise Therapeutics is the larger company by market cap ($4.30 billion vs $3.78 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | TLX |
|---|---|---|
| Share price | $39.57 | $11.12 |
| Market cap | $4.30B | $3.78B |
| 1-day change | -1.12% | +3.15% |
| YTD return | +59.46% | +48.46% |
| 1-year return | +161.36% | +11.76% |
| 5-year return | +123.06% | — |
| P/E ratio (TTM) | — | 111.20 |
| EPS (TTM) | $-1.84 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $803.79M |
| Revenue growth (YoY) | — | +55.61% |
| Net income (latest FY) | $-167.79M | $-7.13M |
| Gross margin | — | 53.05% |
| Operating margin | — | 3.70% |
| Net margin | — | -0.89% |
| 52-week high | $48.51 | $13.11 |
| 52-week low | $14.25 | $6.28 |
| Distance from 52-week high | -18.43% | -15.18% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +32.98% | +83.63% |
| Average volume | 1.35M | 249.35K |
| Shares outstanding | 108.60M | 339.78M |
| Employees | 127 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed TLX by 149.6 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
EWTX vs TLX FAQ
Which is bigger, Edgewise Therapeutics or Telix Pharmaceuticals?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.30B compared with $3.78B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, EWTX or TLX?
EWTX returned +161.36% over the past 12 months, compared with +11.76% for TLX (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.